.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Prof. Dr. Heiner Wedemeyer

Hannover/ DE

Hannover Medical School

Vortrag

25.09.2023
16:35 – 16:50 10 Min. 5 Min.
Highlight-Vortrag
S-3-2
Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D
Chronic Infections

Weitere Beteiligungen

25.09.2023
16:35 – 16:50 10 Min. 5 Min.
Highlight-Vortrag
S-3-2
Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D
Chronic Infections
25.09.2023
17:10 – 17:20 8 Min. 2 Min.
Academy Talk
S-3-5
A novel class of glycan-sensitive human monoclonal antibodies neutralising the hepatitis E virus
Chronic Infections
25.09.2023
Poster
P-1-83
Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions
Chronic Infections
25.09.2023
Poster
P-1-84
Long-term outcome of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International Network (HDIN)
Chronic Infections
25.09.2023
Poster
P-1-88
HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection
Chronic Infections
25.09.2023
Poster
P-1-70
Effects of bile acids on NK cells in HDV patients under Bulevirtide treatment
Immune Prevention and Therapy
25.09.2023
Poster
P-1-95
The impact of cirrhosis on the regeneration of the inflammatory milieu after HCV cure
Chronic Infections
25.09.2023
Poster
P-1-72
Soluble immunological markers correlate with acute inflammation and clinical severity in severe hepatitis ("hepatitis flares")
Immune Prevention and Therapy
25.09.2023
Poster
P-1-99
Polyfunctional hepatitis D virus-specific CD4⁺ T-cell responses are detectable during low viremia time-points in patients chronically infected with the hepatitis D virus
Chronic Infections
25.09.2023
Poster
P-1-102
HBV RNA in the natural course of HBV/HDV coinfection
Chronic Infections
25.09.2023
Poster
P-1-103
DNA methyltransferase inhibition improves the effect of immune checkpoint inhibitors to restore exhausted HBV-specific T cell responses
Chronic Infections
25.09.2023
Poster
P-1-73
Vaccine to Inhibit Autochthonous Transmission of Hepatitis (VaccinATE)
Immune Prevention and Therapy
25.09.2023
Poster
P-1-105
Elevated levels of genome replication of Hepatitis C Virus are associated with response to interferon treatment but do not correlate with viral serum titers or DAA therapy failure
Chronic Infections
25.09.2023
Poster
P-1-75
Blocking viral entry reduces the frequency of Hepatitis Delta virus infected hepatocytes in human liver biopsies
Immune Prevention and Therapy
25.09.2023
Poster
P-1-33
Impact of non-selective beta-blockers on the development of spontaneous bacterial peritonitis (SBP), hepatic decompensation and survival after transjugular intrahepatic portosystemic shunt (TIPS-) insertion
Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions